Litcius/Paper detail

Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease

Ulrik Stervbo, Arturo Blazquez‐Navarro, Elena Vidal Blanco, Lema Safi, Toni Luise Meister, Krystallenia Paniskaki, Mara Stockhausen, Corinna Marheinecke, Gert Zimmer, Jacqueline Wellenkötter, Tina Giglio, Prerna Arora, Stefan Pöhlmann, Markus Hoffmann, Felix S. Seibert, Stephanie Pfaender, Toralf Roch, Timm H. Westhoff, Okan Cinkilic, Nina Babel

2021Kidney International12 citationsDOIOpen Access PDF

Topics & Concepts

VaccinationMedicineEnd stage renal diseaseImmunityPrime (order theory)ImmunologyCellular immunityHumoral immunityDiseaseImmune systemInternal medicineCombinatoricsMathematicsSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyHepatitis B Virus Studies
Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease | Litcius